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Use of Botulinum Toxin in Central Nervous System Disorders
Julie Puvogel, Paige Torbet, Jourdan Ujlaki, Rebecca Worden, Lindsey Peters, PharmD, RPh, BCPS

Abstract
Botulinum toxin is a neurotoxin that is produced by Clostridium botulinum. At one time, this toxin was only seen as a lethal substance, but now scientists have found many medical
uses for it. There are eight distinctive toxins (A-H), but only A
and B currently have clinical uses. Botulinum toxin A has
three different versions that are U.S. Food and Drug Administration (FDA) approved: onabotulinumtoxinA (Botox®),
abobotulinumtoxinA (Dysport®), incobotulinumtoxinA (Xeomin®). Botulinum toxin 8 is also FDA approved as rimabotulinumtoxinB (Myobloc®). The toxins work by inducing
reversible, local, dose-dependent chemodenervation by inhibiting acetylcholine release from presynaptic terminals.
These drugs are approved to treat many different types of
disorders but have found significant use for the treatment of
migraines, dystonias and cerebral palsy. Botulinum toxin has
proven to be efficacious in prophylactically treating those
patients with migraines who have failed other pharmacologic
and nonpharmacologic treatments. Botulinum toxin is also
FDA approved for the treatment of dystonias; more specifically, all three types of botulinum toxin A and the rimabotulinumtoxin B have FDA approval for the treatment of cervical
dystonia. Perhaps the most important use for botulinum toxin is in patients with cerebral palsy. Botulinum toxin is efficacious in patients with upper limb spasticity who are not good
surgical candidates. It also proves useful as an adjunct to
physiotherapy in these patients. This can help reduce or slow
progression in patients with cerebral palsy. Exercise has
been shown to be an efficacious treatment in patients with
migraines, dystonias and cerebral palsy. Further research is
necessary to determine the potential benefits the combination of exercise and botulinum toxin can have in these patients. While the high cost of botulinum toxin might deter
some patients, it is a good option for those that have exhausted other options or are not good candidates for surgery.

therapeutic uses for the toxin. Due to the human body's response to botulinum toxin, Kerner proposed that small
amounts should "reduce or block the hyperactivity and
hyperexcitability of the motor and autonomic nervous
system."1 Since this publication, several researchers have
expanded upon this concept. The explorations of these researchers have resulted in the first successful application of
the gastric tube, the discovery of botulin um toxin-producing
bacteria (Bacillus botulinus, later named Clostridium botulinum) and many additional therapeutic uses of botulinum
toxin, some of which are examined below. In this article, botulinum toxin will be described including which preparations
are currently available. The specific uses of botulinum toxin
will be identified, .and clinical trials will be evaluated for botulin um toxin use in the diagnoses and treatment of migraines, dystonias and cerebral palsy. The progression in the
understanding of this toxin is evident as scientists have
utilized a toxin that was once lethal to now treat numerous
disorders and improve the quality of many lives. Further
research will only continue to unveil new opportunities for
the medical use of botulin um toxin.

Acetylcholine; Acetycholine Release Inhibitors; Botulinum
Toxins Type A; Cerebral Palsy; Chronic Disease; Clostridium
botulinum; Migraine Disorders; Muscle Spasticity; Nerve
Block; Neurotoxins; Pharmaceutical Preparations; Physical
Therapy Modalities; Presynaptic Terminals; Torticollis

Botulinum Toxin
Botulinum toxin is produced by Clostridium botulinum and
includes eight antigenically distinct toxins, labeled A through
H.2 Botulinum toxin is composed of a core neurotoxin and
many nontoxic accessory proteins which protect and stabilize it from temperature changes, variable pH and enzymatic
degradation. The toxin is activated after secretion by scission, either with endogenous or exogenous proteases, and is
then able to induce reversible, local, dose-dependent chemodenervation by inhibiting acetylcholine release from presynaptic nerve terminals. The binding domain of the toxin
binds to presynaptic nerve endings and is internalized via
endocytosis. The catalytic domain, a zinc endopeptidase, is
released in the cytoplasm and irreversibly cleaves proteins
that are essential for regulating exocytosis. This prevents the
acetylcholine vesicles from fusing with the plasma membrane, thus preventing the release of acetylcholine into the
synaptic cleft. It takes approximately three months for new
exocytosis regulating proteins to be resynthesized, which
leads to a full recovery of the neuromuscular junction.

Introduction
The application and knowledge of botulinum neurotoxin has
increased exponentially since its first documentation in 1815
by Professor Johann Heinrich Ferdinand Autenrieth.1 Justinus Kerner made the first major breakthrough in the understanding of botulinum toxin several years later in 1822.
Kerner found and recorded the symptoms of the toxin, hypotheses of pathophysiology and the idea that there were

After years of clinical use and repeated injections of botulinum toxin, sensitization has been known to occur.2 This
sensitization is due to the formation of anti-botulinum toxin
antibodies. These antibodies can be targeted against the core of
botulinum toxin resulting in complete inhibition of the toxin.
However, there can also be antibodies that are targeted against
proteins in the toxin and therefore not interfere with the toxin's biological activity. The formation of these antibodies is the
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main reason to be cautious when using botulinum toxin, as
these antibodies can cause adverse effects for the patient.
There are four main botulinum toxins used as pharmaceuticals: onabotulinumtoxinA (Botox®), abobotulinumtoxinA
(Dysport®), incobotulinumtoxinA (Xeomin®) and rimabotulinumtoxinB (Myobloc®).2 They differ in purity, potency, immunogenicity, complexity and manufacturing.
There are many U.S. Food and Drug Administration (FDA)
indications for the use of botulinum toxin (summarized in
Table 1).3 Botulinum toxin is considered a first-line treatment in patients with cervical dystonia (CD) which presents
as a combination of dystonic movements and postures and,
frequently, pain.2 The first choice of therapy for patients with
blepharospasm, an involuntary closure of the eyelids, is also
botulinum toxin; safety and efficacy have been proven in clinical trials. There is also strong evidence in support of using
botulinum toxin for upper limb spasticity. A common FDA
approved indication is the treatment of glabellar lines, more
commonly referred to as "frown lines."3 Other indications
vary according to which toxin is being used. OnabotulinumtoxinA has the most indications, other than those al-
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ready mentioned, including axillary hyperhidrosis, chronic
migraine, lateral canthal lines, lower limb spasticity, overactive bladder, strabismus and blepharospasm associated with
dystonia and urinary incontinence due to detrusor overactivity.3
Adverse reactions to botulinum toxins can occur.3 The incidence of the adverse reaction depends on what the toxin is
being used to treat as well as the brand of the toxin. Some
more prominent adverse reactions that have been reported
to be caused from botulinum toxin include urinary tract infection, urinary retention, headache, neck pain, injection site
irritation, upper respiratory tract infection, dizziness and
strabismus. Botulinum toxin is associated with an administration warning: botulinum toxin can spread beyond the
site of injection and can cause life threatening injury such as
dysphagia.
Botulinum toxin is dosed in units, and it is recommended
that the lowest dose should be used when initiating treatment and increasing the dose as necessary to alleviate symptoms of disease.3 No dose adjustments are required for
patients with renal or hepatic impairment. The onset of ac-

Table 1. A Summary of Available Botulinum Toxins.3
Generic Name
(Brand Name)

AbobotulinumtoxinA
(Dysport®)

lncobotulinumtoxinA
(Xeomin®)

OnabotulinumtoxinA
(Botox®)

RimabotulinumtoxinB
(Myobloc®)

Botulinum
Toxin Type

Type A

Type A

Type A

TypeB

Axillary hyperhidrosis
(severe); blepharospasm
associated with dystonia;
cervical dystonia; migraine
(chronic) prophylaxis;
overactive bladder;
strabismus; upper limb
spasticity (severe); urinary
incontinence (due to
detrusor overactivity
associated with a neurologic
condition)
Cosmetic: Glabellar and
lateral canthal lines
(moderate to severe)

Cervical dystonia

Injection,
powder for solution

Injection,
solution

Blepharospasm,
cervical dystonia,
glabellar lines
(moderate to
severe),
upper limb spasticity

Labeled
lndication(s)

Cervical dystonia;
glabellar lines
(moderate to
severe)

Dosage Forms
Available

Injection,
powder for solution

Injection,
powder for solution

Dosage
Strengths
Available

300 and 500 units

SO, 100 and
200 units

100 and 200 units

2,500 units per 0.5
mL;
5,000 units per 1 mL;
10,000 units per 2 mL

Route of
Administration

IM

IM

IM, intradermal,
intradetrusor

IM

Adapted from: Lexicomp [Internet]. Hudson (OH) : Wolters Kluwer. 2016.
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tion, represented by improvement of symptoms, can occur
anywhere from days after injection to weeks after injection
and is dependent on the toxin used. The toxin typically has a
duration of months but is also dependent on toxin used and
indication.
It should be noted that botulinum toxin is costly. Depending
on the brand, botulinum toxin can cost around $700 for 100
units.3 Insurance coverage varies, though most insurances
require a patient to be nonresponsive to at least one treatment prior to trying botulinum toxin.4 In light of this, cost
can be a major barrier to treatment for patients and should
be weighed against other, less-costly treatment options.

A review follows of the current nonpharmacologic and pharmacologic treatment options for the three common indications: migraine, dystonia and cerebral palsy. An evaluation of
the literature for both safety and efficacy is also included. A
summary of the trials discussed is shown in Table 2.
Migraines
The prevalence of migraines varies by age and gender, but in
the United States it is reported that more women than men
experience migraine headaches.5 It has been reported that
prevalence is highest in patients between 30 and 49 years of
age.
The etiology and pathophysiology of migraines are not completely understood, however, most clinicians believe the
pathogenesis may be related to complex dysfunctions in
neuronal and broad sensory processing.s The pain due to
migraines is thought to come from activity within the trigeminovascular system, which is a network of visceral afferent
fibers arising from the trigeminal ganglia and projects peripherally to innervate pain sensitive cranial blood vessels,
dura mater and large venous sinuses. These fibers also project centrally where they terminate in the trigeminal nucleus
caudalis in the brainstem and upper cervical spinal cord
providing a pathway for nociceptive transmission to the
higher centers of the central nervous system (CNS). Activation of trigeminal sensory nerves releases vasoactive neuropeptides, which interact with dural blood vessels to promote
vasodilation and dural plasma extravasation, causing neurogenic inflammation. Conduction along the trigeminovascular
fibers transmits pain inputs to the trigeminal nucleus caudalis where the pain information is relayed to higher pain centers. Continued afferent input can cause sensitization of the
central sensory neurons which produces a state that maintains the headache. It is thought that those who experience
migraines have a lower threshold of response to specific environmental factors that govern the balance of CNS excitation
and inhibition. The responsiveness of the migrainous brain
may be due to genetic factors that cause abnormalities in ion
channels and pumps that control the release of neurotransmitters in the brain.
Treatment strategies for migraines are generally individualized, based on the patient's long-term and short-term goals,
and usually aim to minimize headache-related disability and
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distress to improve the patient's quality of Iife.5 In general,
treatment includes both pharmacologic and nonpharmacologic options that are both prophylactic and symptomatic
and depend on the severity of the migraine. It is noted when
migraine medications are used frequently and/or excessively, a phenomenon occurs in which the headache symptoms
recur with increased frequency or intensity. This is known as
"rebound headaches" or "medication overuse" headaches.
No specific treatments have been shown to be effective for
this other than tapered withdrawal of the medications being
overused.
Nonpharmacologic treatment for migraines can include
keeping a headache journal to identify triggers to avoid, performing behavioral interventions such as relaxation therapy,
and adhering to a general wellness program including sleep,
exercise, healthy eating, smoking cessation and limiting caffeine intake.s The effects of aerobic exercise and yoga on migraine severity and recurrence are based on limited research.
According to a review of literature on these and other
alternative treatment methods, studies have found opposing
results, but recent research has shown positive effects on
reduction of migraine symptomology.6 In a study of 72
patients with migraines, headache intensity, medication use
and pain ratings were found to be significantly lower
(P <0.001) in the group who completed 12 weeks of 60
minutes of yoga five times a week versus the control group.7
Additionally, the intervention group displayed a significant
decrease in anxiety and depression (P <0.001). A Turkish
study examined the relationship between migraines and aerobic exercise delivered in three (one hour) sessions per week
and reported that the severity, frequency and duration of
migraines were decreased with regular activity compared to
the control group.a Additional information regarding these
and alternative treatment methods can be obtained from
Karakurum Goksel's review of therapeutic options for migraine patients.6 Due to the lack of research on these topics,
the combination of botulinum toxin and exercise has not
been examined. Further research should be conducted to
determine whether the benefits of each treatment can be
additive or synergistic for greater gains in symptom relief.
Common pharmacologic treatments include analgesics and
nonsteroidal anti-inflammatory drugs (NSAIDs).s Serotonin
receptor agonists, such as sumatriptan, are also used as migraine relief medications. Migraine relief is a result of normalizing dilated intracranial arteries, inhibiting vasoactive
neuropeptide release and inhibiting transmission to the thalamus. Beta adrenergic antagonists are most widely used for
migraine prophylaxis. While the precise mechanism of how
this class of drug prevents migraines is unknown, it is
thought that they may raise the migraine threshold by
modulating adrenergic or serotonergic neurotransmission in
cortical or subcortical pathways. Antidepressants are also
potentially beneficial in migraines most likely due to the
downregulation of central serotonin receptors, increased
levels of synaptic norepinephrine and enhanced endogenous
opioid receptor actions. Anticonvulsants are emerging as an
option in treating migraines, especially in patients who also
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Table 2. Summary of Studies Discussed.

Authors

Study Design

Disease State
Studied

Main Endpoints

Author's Conclusions

Randomized,
double-blind,
placebo controlled

Migraines

Change in number of
headache days

Botox® is an effective prophylactic
treatment in migraine patients who
are not using any other prophylactic
migraine medications.

Jankovic J,
Adler CH,
Charles D,
et al. 14

Prospective,
observational,
multicenter
registry

Cervical
Dystonia

Clinical safety and
efficacy of onabotulinumtoxinA in cervical
dystonia

OnabotulinumtoxinA is safe and
efficacious in the treatment of cervical
dystonia.

Evidente VGH,
Fernandez HH,
LeDoux MS,
et al. 15

Randomized,
double-blind,
repeated-dose

Cervical
Dystonia

Efficacy and safety of
incobotulinumtoxinA for
cervical dystonia in
repeated doses

lncobotulinumtoxinA is safe and
efficacious in the treatment of cervical
dystonia.

TruongD,
BrodskyM,
LewM,
et al.16

Randomized,
double-blind,
placebo
controlled

Cervical
Dystonia

Long-term efficacy and
safety of Dysport®

Dysport® is safe and efficacious in
long-term treatment of cervical
dystonia.

DresslerD,
Tacik P,
Saberi FA17

Prospective,
open-label
crossover study

Cervical
Dystonia

Comparing potency of
the drugs Botox® and
Xeomin®

Similar therapeutic effect durations;
doses were exchanged ata 1:1 ratio,
concluded similar efficacy and potency.

YunJY,
KimJW,
Kim HT,
et a1.1a

Randomized,
double-blind,
multicenter,
non-inferiority,
two-period
crossover study

Cervical
Dystonia

Compared Dysport® and
Botox® by looking at
changes in TWSTRS and
Tsui scale scores

No significant difference between
groups in the TWSTRS ratings or the
Tsui scale; concluded that Dysport®
and Botox® are comparable at dosage
conversion of 2.5:1.

Koman LA,
Smith BP,
Williams R,
et al. 24

Randomized,
double-blind,
placebocontrolled

Cerebral palsy
(upper limb)

Assess efficacy of
botulinum toxin A on
Upper Extremity Rating
scale, HC, Modified
House Functional
Classification and
Melbourne Assessment
of Unilateral Upper Limb
Function of patients

Those that received therapy had
statistically significant improvement
in the Melbourne Assessment
compared to placebo, authors
concluded that it was safe and a good
option for patients who are not good
candidates for surgery.

Ferrari A,
MaoretAR,
Muzzini S,
et aJ. 2 5

Randomized
placebocontrolled

Spastic
hemiplegic
upper limb
cerebral palsy

Study the effects of
botulinum toxin
combined with
physiotherapy measured
by the Assisting Hand
Assessment (AHA)

Botulin um therapy was significantly
better than placebo when combined
with physiotherapy.

DodickDW,
MauskopA,
Elkind AH,
et al.4
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experience seizures, anxiety and bipolar illness. These agents
are thought to be beneficial due to the modulation of the
excitatory neurotransmitter glutamate and inhibition of sodium and calcium ion channel activity.
Botulinum toxin has been shown to inhibit the release of nociceptive mediators, causing anti-nociceptive action separate
from its neuromuscular activity.s Also, botulinum toxin has
been shown to inhibit sensitization of central trigeminovascular neurons, which is felt to be important in the development, progression and maintenance of migraines. Thus,
botulinum toxin has been an area of research for prophylaxis
of migraine headaches.
A randomized, double-blind, placebo-controlled study of 355
patients experiencing 16 or more headache days during a
30-day baseline period was conducted.4 The study included a
30-day baseline period, followed by a 30-day, single-blind,
placebo-run-in period in which placebo response was determined, followed by a nine month, double-blind treatment
period in which patients received three treatment cycles of
either Botox® or placebo, separated by 90 days. During the
study, characteristics of the patient's headaches were recorded using an electronic telephone diary. The participants in
the study were grouped into those taking prophylactic medications and those that were not. Of those that were not taking any prophylactic medication, 117 received the botulinum
toxin and 111 received placebo. Analysis of these 228 patients was conducted. At baseline, the number of headachefree days between these placebo and treatment groups were
similar. The increase in headache-free days for the botulinum
toxin group was 10 days, compared to the placebo group of
6.7 days, and was statistically significant with a p-value of
0.038. Mean usual headache severity decreased over the
course of the study for both the placebo and the treatment
group. However, the decrease was greater in the botulinum
toxin group and was statistically significant from day 180 to
day 270. This study also evaluated the use of acute headache
pain medication in addition to either the toxin or the placebo.
It was found that there was a statistically significant difference between the placebo and toxin group in the use of pain
medication. The placebo group decreased by only 4.1 days,
compared to the toxin group, which decreased its use of pain
medication an average of 7.8 days. This study showed that
headache symptoms improved in patients receiving botulinum toxin in all efficacy parameters studied.
Jn another study, Mitchel and colleagues looked into the costeffectiveness and quality of life (QOL) improvements in using
botulinum toxin to treat refractory migraine headaches.9 Surveys were sent to 54 patients, and 32 were returned. The
survey included six QOL measures: headache severity, headache frequency, use of rescue medications, productivity/
absenteeism, recreational activities and life enjoyment. Participants used a five-point scale to assess those categories,
which were no improvement, little improvement, moderately
improved, quite a bit improved, or extremely improved. A
composite QOL score was calculated by summing up the
measures for each category, and 73 percent of participants
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reported moderate or better improvement in overall
migraine QOL measures. However, analysis of total migrainerelated pharmacy costs (cost of the toxin and overall migraine-related medications) shows that costs went up by
80.9 percent after initiating toxin treatment. There was no
change in the number of migraine-related emergency room
visits. Limitations with this study include a short
follow-up period, the use of concomitant pain medications
and no comparison group.
For the treatment of chronic migraines, botulinum toxin appears to be as effective as current therapy, with a decreased
need for additional pain medications. More large scale research needs to be performed with standardization of injection site location and dosage to solidify efficacy and safety of
the toxin and determine if there is a place for using the toxin
to treat refractory migraines.

Dystonias
Dystonia is a type of prolonged muscle tone that presents in
patients in many different ways and can be mistakenly diagnosed as Parkinson's disease due to the repetitive and shaky
movements with which some people presenuo.11 Due to the
underdiagnosis of dystonia, often due to misdiagnosing, the
true prevalence is hard to calculate.10 The hallmark symptoms of dystonias are dystonic postures and movements
(flexing or twisting movements, rigidity), sensory tricks (a
trick is touching the affected body part to relieve dystonia),
mirror dystonias (repetitive movements occur in a nonaffected limb) and overflow dystonias (dystonia occurring in an
atypical body region for the patient). 11 The etiology is broken
down into multiple parts, so it is important to classify the
cause and type of dystonia in order to improve quality of life
for the patient. The 2011 guidelines for dystonia provide a
classification system to differentiate the types instructing
clinicians to look at the etiology of the dystonia, the age of
onset (early or late) and the distribution (focal, segmental,
multifocal, generalized or hemidystonia).10 Genetic testing
can be done on symptomatic individuals to diagnose certain
types of dystonia as well. For the most part, each type of dystonia has its own validated rating scale to evaluate the disease, monitor progression and predict impact on quality of
life.
In general, nonpharmacologic treatment options that are
utilized include occupational therapy, physical therapy, deep
brain stimulation and selective peripheral denervation and
myectomy. 12 Common medication classes that doctors prescribe for dystonias are skeletal muscle relaxants (especially
intrathecal baclofen), anticholinergic drugs, anticonvulsant
drugs, anti-dopaminergic drugs and dopaminergic drugs. The
guidelines do suggest the use of botulinum toxin for different
types of dystonias. As mentioned above, all three formulations of botulinum toxin A and botulinum toxin B are FDA
approved for the treatment of cervical dystonia (CD).10.13
OnabotulinumtoxinA (Botox®) had previously been the gold
standard in cervical dystonia treatment. It was the first botulinum toxin that the FDA approved and has demonstrated
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safety and efficacy in a prospective, observational registry
that tracked 502 patients receiving Botox® for cervical
dystonia.14 lncobotulinumtoxinA (Xeomin®) is a newer
preparation of botulinum toxin that does not have accessory
proteins, which helps prevent possible immunogenicity
problems. It, too, has shown to be efficacious and safe in a
double-blind, repeated-dose 88 week study.is Similarly, the
third type ofbotulinum toxin, abobotulinumtoxinA (Dysport®)
demonstrated efficacy in a randomized, double-blind, placebocontrolled study, followed by an open-label extension. 16
Botulinum toxin B was noninferior to Botox® for the treatment
of cervical dystonia in a randomized, double-blind, noninferiority trial.13 Therefore, in today's practice, botulinum toxin B
can be used as an alternative to botulinum toxin A.10
Because all three types ofbotulinum toxin A are safe and efficacious, studies are now comparing the different types. In a
prospective, open-label crossover study comparing Botox®
and Xeomin®, researchers compared the time between the
injection and when the patient reported a decrease in the
therapeutic effect.17 They also compared the potency of the
two drugs by giving participants at least four injection series
of each drug at a 1:1 dose ratio. The mean time to decrease in
therapeutic effect was 11.2 ± 1.1 weeks for Botox®, compared to Xeomin®, which had a time to decrease in effect of
11.4 ± 1.3 weeks. Researchers concluded that because there
were similar therapeutic effect durations and that the doses
were exchanged at a 1:1 ratio, Botox® and Xeomin® have
similar efficacy and potency.

CNS

mine the best option for a patient. In a cost-utility analysis,
authors compared Botox®, Dysport® and Xeomin® use in cervical dystonia from a federal government payer perspective.
Outcomes were evaluated by measuring quality-adjusted life
years (QALYs).20 Assuming a willingness-to-pay value of
$100,000 per QALY, all three formulations are considered
cost-effective; however, the most effective was Xeomin®
with a cost-effectiveness ratio of $27,548 per QALY, followed
by Dysport® ($36,678), and Botox® ($49,337). The QALY
gained in a one-year period was comparable with 0.06 QAL Y
gained for Dysport® and 0.07 QAL Y gained for both Xeomin®
and Botox®. The authors of the analysis also looked at wastage
during injections because each manufacturer recommends
using one vial per patient. Dysport® had the lowest wastage
(2.2 percent) followed by Xeomin® (10 percent) and Botox®
(22.9 percent). Xeomin® has an advantage over Botox®; it is
available in SO unit vials, whereas the smallest vial available
for Botox® contains 100 units. The 50 unit vial allows for dose
individualization with less waste. This analysis provides a useful comparison between the drugs from a cost perspective.
A current area of dystonia research surrounds the
combination of exercise and botulinum toxin injections. Induced muscle weakness can result from botulinum toxin due
to neuroparalysis and denervation.21 Inclusion of treadmill
training programs has been assessed in rats to examine the
results of this combination. Researchers found that exercise
diminished muscle atrophy following injections and positively affected muscle contractile strength recovery. There is a
possibility that treadmill training could cancel out the
response of spasticity reduction from the botulinum toxin
injection. The current knowledge base does not include research that has confirmed or denied these theories in human
participants. Due to the nature of both methods, this relationship should be explored to determine the effect on patients
with muscle spasticity, including patients with dystonias.

Similarly, researchers compared Dysport® and Botox® in a
randomized, double-blind, multicenter, noninferiority, twoperiod crossover study.1s The purpose of this study was to
determine if a 2.5:1 ratio was an adequate conversion by
looking at changes in the Tsui scale and the Toronto Western
Spasmodic Torticollis Rating Scale (TWSTRS) from baseline
to follow-up (weeks 4, 8, 12, and 16). The Tsui scale is a short
rating system that looks at sustained movement amplitudes,
duration, shoulder elevation and dystonic tremor but does
not assess how cervical dystonia affects a patient's daily
life.19 The TWSTRS is a validated scale that does look at the
impact on a patient's life by summing up three different categories related to the participants' experience with cervical
dystonia: severity, disability and pain.16 They also evaluated
the participants' preferences and the reasons for their preferences.rn There was no significant difference between
groups in the TWSTRS ratings, and while participants' ratings in the Tsui scale favored Botox®, the difference was not
significant. When asked, more participants chose Dysport®
(n=36) to Botox® (n=34), and 21 participants said they did
not have a preference. In both cases of preference, the main
reason that was given by patients was a perceived increase
in efficacy. Adverse events were not statistically different
between the two groups. Because neither version had a statistically significant preference, both drugs are comparable at
a dosage conversion of 2.5:1 Dysport® to Botox®.

Cerebral Palsy
Cerebral palsy is a debilitating disease that starts in infancy
or young children.2 2 Currently, it is the number one cause of
childhood disabilities. The disease begins when damage occurs to the cerebral cortex either during fetal development,
during birth, or after birth and is permanent. Types of damage could be periventricular leukomalacia, cerebral dysgenesis, intracranial hemorrhage or a lack of oxygen. It manifests
in a variety of symptoms such as limb weakness, spasticity,
crouched gait, ataxia and delays in reaching motor skill milestones. Every patient with cerebral palsy will have individualized presentation and severity of the disease. Doctors can
diagnose the disease by testing motor skills, monitoring motor development and performing neuroimaging techniques
like cranial ultrasounds, computed tomography (CT) and
magnetic resonance imaging (MRI). While this disease is not
curable, botulinum toxin has become a standard of treatment
for cerebral palsy patients of all ages to help improve gait
function by controlling spasms.

Since the three forms are all efficacious, safe and comparable,
it is important to consider the cost-effectiveness to deter-

Nonpharmacologic options might include surgeries like rhizotomy to kill certain nerve roots responsible for cerebral
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palsy or peripheral neurectomy to remove the nerves.23 Orthopedic surgical options might include tendon lengthening
or transfer, osteotomy or joint fusion to help with movement.
Oral treatment options for cerebral palsy include dantrolene
sodium, baclofen, tizanidine and benzodiazepines. Patients
can also receive parenteral therapy to aid in chemical denervation, such as ethanol 45 to 100 percent, phenol S to 7 percent, botulinum toxin or intrathecal baclofen. Because not all
patients are good surgical candidates, and botulinum toxin is
not something a patient has to receive every day, it becomes
a good option for many patients.
Children with cerebral palsy that affects their upper extremities often have spasticity patterns like internal shoulder rotation, elbow flexion, forearm pronation, wrist and finger flexion and thumb-in palm.24 Many of these patients are not good
candidates for surgery due to their age, so botulinum toxin
therapy would be a good option to help control spasms until
they are a better candidate for surgery. In a randomized,
double-blind, placebo-controlled study of botulinum toxin A,
researchers used the House Classification (HC) system to
rate participants' functional ability. The participants received
either botulinum toxin A or placebo at baseline, week 8, and
week 20 if indicated. Visits were conducted at baseline and
weeks 4, 8, 14, 20 and 26. At the visits where the patient received an injection, the patient met independently with both
a physician and an occupational therapist, and if the visit did
not include an injection, the patient was evaluated by just the
occupational therapist. Doses were individualized to the patient, and if the physician felt that the patient did not need
another injection the injection was not given at that appointment. The physician evaluated based on the Upper Extremity
Rating scale (used to evaluate the range of motion of the
limbs), the HC, and the Modified House Functional Classification. The occupational therapist used these same scales along
with the Melbourne Assessment of Unilateral Upper Limb
Function. The study also looked at Health-Related Quality of
Life outcomes for the caregivers and also safety of botulin um
toxin A by assessing any adverse events.
The study showed that the patients in the botulinum toxin A
group had a statistically significant improvement in the Melbourne Assessment compared to placebo.24 The study also
showed a better improvement in the mean range of motion
at weeks 20 and 26 for the botulinum toxin A group. There
was not, however, any difference in the Health-Related Quality of Life data for the caregivers. Botulinum toxin A did prove
to be relatively safe for the patients in the study with only
mild to moderate adverse events reported such as muscle
soreness at the injection site, muscle cramps, excessive
weakness, headache, rash and fatigue. Overall, the study
proved that botulinum toxin A is a good option for those patients with upper limb spasticity related to cerebral palsy
that are not currently candidates for surgery.
In a similar randomized, placebo-controlled trial, botulinum
toxin was compared with placebo in children with spastic
hemiplegic upper limb cerebral palsy.zs One of the major differences in the study was that the injections were combined
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with physiotherapy. The participants received injections at
baseline and had follow-up visits at one, three and six
months. The participants also had a physiotherapy program
that included three (45 minute) weekly sessions for 24
weeks. The program included activities started out as unimanual and then moved bimanual and more complex as the
study progressed. After the injection, participants received a
customized positional splint. The study used the Assisting
Hand Assessment (AHA) scale as a primary outcome to
measure the use of the affected upper limb. Both the placebo
group and the botulinum toxin A group showed improvement in the AHA score after receiving an injection and physiotherapy, but the botulinum toxin A group showed a faster
and more substantial change. At the six month visit, the botulinum toxin group stopped showing improvement, while the
placebo group continued to change. This correlates with other studies that concluded that the average length of effectiveness for botulinum toxin injections is around 12 weeks.17
Because this study was small (only 27 participants), further
studies need to be done on larger groups over a longer period of time; however, this study did confirm that botulinum
toxin is effective in these patients, and that physiotherapy
works as an adjunct when individualized to each patient.Zs
The treatment of cerebral palsy can vary due to the patient's
needs. One common component of cerebral palsy treatment
is exercise. It has been found that the inclusion of treadmill
exercises benefits the symmetry, speed and endurance of
cerebral palsy patients.26 Spasticity of muscles results in
weak lower extremity muscles and bone development due to
the delay in independent ambulation. In a study of 37 children with diagnosed cerebral palsy, an experimental group
completed treadmill sessions twice a week for three months
in addition to rehabilitation programs twice a week. At the
conclusion of the study, the results between the treadmill
program participants and the control group, who did not exercise, were compared. Participants who completed treadmill exercise were able to walk significantly faster, longer
and farther during the postparticipation testing (p<0.001).
The results of this study supported the conclusion that had
been found and documented previously; ambulation and exercise tolerance are improved with the inclusion of treadmill
exercise. Various exercise methods were examined for effects
on postural control of cerebral palsy patients in a metaanalysis performed by Dewar, Love and Johnston.27
Treadmill training was supported as well as gross motor task
training, hippotherapy, trunk-targeted training and reactive
balance training.
In theory, the combination of exercise and botulinum toxin
should compound the benefits of these treatments and reduce the potential adverse effect of nontargeted muscle
weakness. In a study of 15 children, 10 weeks of a home
strength program were performed three times a week in patients who also received Botulinum Type-A (BoNT-A) injections.zs Significant results were documented in both groups
that participated in the exercise program; one before the injections and the other after. The levels of muscle spasticity
were reduced, in addition to increased strength in the exer-
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cise and BoNT-A combined treatment group. As recorded in
this study, the inclusion of exercise in conjunction with botulinum toxin injections can have a profound impact in cerebral
palsy patients. Further research should continue to examine
the timing, exercise method and other types of botulinum
toxin for optimal treatment development.

Conclusion
Botulinum toxin has been established as an integral part in
the treatment of disorders caused by muscle overactivity.
Many clinical trials, shown in Table 2, have confirmed the
safety and efficacy of its use. The benefits of the botulinum
neurotoxin in the treatment of migraines, dystonias and cerebral palsy are only some of the uses for the toxin in the
health care field. Botulinum toxin has also been included in
the treatment of many ophthalmological disorders and
movement disorders and continues to undergo testing for
applications in smooth muscle overactivity disorders and
hypersecretion of glands.29 Although some adverse effects
can occur, the discovery and use of this toxin has led to a
higher quality of life for many patients with various disorders. The use of this drug in combination with other forms of
treatment has the potential for even greater outcomes for
patients. Further research will increase the impact botulinum toxin will have on the progression of treatments for disorders of spasticity.
References
1.
Erbguth F. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord.
2004 Mar; 19(Suppl 8):S2-6.
2.
Bentivoglio AR, Del Grande A, Petracca M, Ialongo T, Ricciardi L. Clinical differences between botulinum neurotoxin type A and B. Toxicon.
2015 Dec; 107:77-84.
3.
Lexicomp [Internet]. Hudson (OH): Wolters Kluwer. 2016. Neuromuscular blocker agent, toxin; [2016; 20 Feb 2016]. Available from:Oonline.lexi.com.polar.onu.edu/lco/action/search/pharmacat/patch_f?
q=Neuromuscular+Blocker+Agent%2C+Toxin.
4.
Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD.
Botulinum toxin type A for the prophylaxis of chronic daily headache:
subgroup analysis of patients not receiving other prophylactic medications: a randomized, double-blind, placebo-controlled study. Headache.
2005 April; 45:315-24.
5.
DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors.
Pharmacotherapy: a pathophysiologic approach [Internet]. 9th ed. New
York: McGraw-Hill; 2014. Chapter 45, Headache Disorders; [cited 2016
Feb 20]; [about 20 screens]. Available from:O-accesspharmacy.mhmed
ical.com.polar.onu.edu/content.aspx?bookid=689&sectionid=45310495.
6.
Giiksel, BK. The use of complementary and alternative medicine in
patients with migraine. Noro Psikiyatr Ars (Archives of Neuropsychiatry). 2013 Sept; 41-6.
7.
John PJ, Sharma N, Sharma CM, Kankane A. Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled
trial. Headache. 2007 May; 47(5):654-61.
8.
Narin S, Pinar L, Erbas D, Oztiirk V, Idiman F. The effects of exercise and
exercise-related changes in blood nitric oxide level on migraine headache. Clin Rehabil. 2003 Sept; 17(6):624-30.
9.
Mitchell MP, Schaecher K, Cannon HJl, Speckman M. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for
treatment of refractory migraine headaches in a managed care organization. J Manag Care Pharm. 2008 June; 14(5):442-50.
10. Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, et al. EFNS
guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011; 18:5-18.
11. Albanese A, Lalli S. Is this dystonia? Mov Disord. 2009; 24(12):1725-31.
12. Albanese A, Barnes MP, Fernandez-Alvarez E, Filippini G, Gasser T,
Krauss JK, et al. A systematic review on the diagnosis and treatment of

Summer 2016 Volume 7, Issue 3

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

CNS

primary (idiopathic) dystonia and dystonia plus syndromes: report of
an EFNS/MDS-ES task force. Eur J Neurol. 2006; 13:433-44.
Pappert EJ. Germanson T. Botulinum toxin type B vs. type A in toxinnaive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008; 23(4):510-17.
Jankovic J, Adler CH, Charles D, Comella C, Stacy M, Schwartz M, et al.
Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE). J Neurol Sci. 2015;
349:84-93.
Evidente VGH, Fernandez HH, LeDoux MS, Branshear A, Grafe S,
Hanschmann A, Comella CL. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin) in cervical dystonia. J Neural
Transm. 2013; 120:1699-707.
Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, et al.
Long-term efficacy and safety of botulinum toxin type A (Dysport) in
cervical dystonia. Parkinsonism Relat Disord. 2010; 16:316-23.
Dressler D, Tacik P, Saberi FA. Botulinum toxin therapy of cervical
dystonia: comparing onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin). J Neural Transm. 2014; 121:29-31.
Yun JY, Kim JW, Kim HT, Chung SJ. Kim JM, Cho JW, et al. Botox at a ratio
of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
Mov Disord. 2015; 30(2): 206-13.
Jost WH, Hefter H, Stenner A. Reichel G. Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulin um
toxin therapy. J Neural Transm. 2013; 120(3):487-96.
Kazerooni R, Broadhead C. Cost-utility analysis ofbotulinum toxin type
A products for the treatment of cervical dystonia. Am J Health-Syst
Pharm. 2015; 72:301-7.
Tsai SW, Chen HL, Chang YC, Chen CM. Molecular mechanisms of treadmill therapy on neuromuscular atrophy induced via botulinum toxin A.
Neural plasticity. 2013 Nov 12;2013.
National Institute of Neurological Disorders and Stroke [Internet].
Bethesda, MD: National Institute of Health; Cerebral palsy: hope
through research; [updated 2016 Mar 16; cited 2016]; [about 12
screens]. Available from:www.ninds.nih.gov/disorders/cerebral_palsy
/detail_cerebral_palsy.htm.
Koman LA, Paterson Smith B, Balkrishnan R. Spasticity associated with
cerebral palsy in children: guidelines for the use of botulinum A toxin.
Paediatr Drugs. 2003; 5(1):11-23.
Koman LA, Smith BP, Williams R, Richardson R, Naughton M, Griffin L,
Evans P. Upper extremity spasticity in children with cerebral palsy: a
randomized, double-blind, placebo-controlled study of the short-term
outcomes of treatment with botulinum a toxin. J Hand Surg. 2013;
38A:435-46.
Ferrari A, Maoret AR, Muzzini S, Alboresi S, Lombardi F, Sgandurra G, et
al. A randomized trial of upper limb botulinum toxin versus placebo
injection, combined with physiotherapy, in children with hemiplegia.
Res Dev Disabil. 2014; 35:2505-13.
Sarita~ N, Abakay H, Karaku~ M, Co~kun B. Somatotype profiles and
changes depending on treadmill exercise in children with cerebral
palsy. Journal of Physical Education & Sports Science. 2014 Aug; 8
(2):207-14.
Dewar R. Love S, Johnston L. Exercise interventions improve postural
control in children with cerebral palsy: a systematic review. Dev Med
Child Neurol. 2015 June; 57(6):504-20.
Williams SA, Elliott C, Valentine J, Gubbay A, Shipman P, Reid S. Combining strength training and botulinum neurotoxin intervention in
children with cerebral palsy: the impact on muscle morphology and
strength. Disabil Rehabil. 2013 April; 35(7): 596-605.
Miinchau A. Bhatia KP. Uses of botulinum toxin injection in medicine
today. BMJ (Int Ed). 2000 Jan 15; 320(7228):161-5.
The authors have no conflict of interest or funding support to disclose.

THE PHARMACY AND WELLNESS REVIEW

33

